A process for analysing chromosome regions and interactions relating to prognosis of prostate cancer or DLBCL.

The invention provides a method of establishing a chicken methylation clock comprising: (a) determining the methylation ratio and the read coverage of the genomic CpG sites of an age-correlated training sample of a specific chicken tissue; (b) defining a set of CpG sites having reliable methylation ratios in all training samples of step (a) using a cutoff value; and (c) performing a penalized regression using the methylation ratios of step (b) as input and the age correlated to the training sample as dependent variable, by applying a penalized regression model; thereby obtaining a set of CpG sites with corresponding weighting factors and intercept of the linear model equation as parameters defining the chicken methylation clock.

Provided herein are methods and kits for detecting the presence of DNA and/or RNA mutations associated with cancer (e.g., lung cancer). The methods and kits employ microcarriers, each with a probe specific for a DNA or RNA mutation and an identifier unique to the probe sequence. Upon isolation and amplification of nucleic acids from a sample, hybridization of amplified DNA with a probe, specific for a DNA or RNA mutation, that is coupled to a microcarrier indicates the presence of the mutation in the sample. Since each microcarrier can be identified through detection of the identifier, multiplex screening assays are provided. Representative genes that can be screened for mutations include, e.g., KRAS, NRAS, PIK3CA, BRAF, EGFR, AKT1, MEK1, and HER2 for DNA mutations and/or ALK, ROS, RET, NTRK1, and cMET for RNA mutations.

Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.

A method for in vitro predicting of the outcome of an individual having a multiple myeloma, including the steps of: a) measuring the expression level of at least 5 genes and/or proteins encoded by the 5 genes, the genes being selected in a group including NRP2, REEP1, SV2B, ARRB1, CACNA1G, FBLIM1, FGFR1, IRF6, ITGA9, NOVA2, PPP2R2C, SLC5A1, SORL1, SYT7 and THY1, in a biological sample obtained from the individual; b) calculating a score value from the expression level obtained at step a); c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.

The present invention includes a method for analyzing RNA fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat a disease or condition, disease recurrence, or disease progression comprises characterizing the identity of rRNA fragments. The invention also includes diagnosing, identifying or monitoring a disease or condition, and a method for identifying rRNA fragments. The invention also includes diagnosing, identifying or monitoring a glaucoma in a subject in need thereof by characterizing the identity of rRNA or tRNA fragments.

The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.

The invention is directed to biomarkers for predicting a patient's response, both therapeutic and toxic, to immunotherapy.

Described herein are compositions, methods, and techniques to generate a cancer signature and uses thereof. The cancer signature can be used to determine a cancer progression risk of a subject based upon expression levels of genes of a progression gene signature in a sample. The methods can be used to predict a prognosis, to select an appropriate treatment regimen, to identify or screen for an agent effective against a cancer, or a combination thereof. Computer implemented methods and systems that implement those methods are also provided. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The disclosure provides a method for or the early diagnosis, prognosis and differentiation of myocardial infarction (MI). The method comprises performing genetic analysis on gut microbiota. The disclosure also provides a biomarker and kit for the early diagnosis, prognosis, recurrence and differentiation of MI.